Advertisement

Treatment-related osteoporosis in men with prostate cancer

  • Maryanne Kazanis
  • Matthew R. Smith
Drug-Induced Osteoporosis
  • 32 Downloads

Abstract

Osteoporosis is an important complication of androgen-deprivation therapy (ADT) for prostate cancer. ADT by either bilateral orchiectomies or treatment with a gonadotropin-releasing hormone (GnRH) agonist decreases bone mineral density (BMD) and increases the risk of fracture. Prospective data about treatment or prevention of osteoporosis in men with prostate cancer are limited. Supplemental calcium and vitamin D are recommended. Additional therapy may be warranted for men with osteoporosis or fractures. Intravenous pamidronate prevents bone loss in the hip and spine during ADT. Intravenous zoledronic acid not only prevents bone loss but also increases BMD. Alendronate is approved to treatmen with osteoporosis although the efficacy of alendronate or other oral bisphosphonates has not been evaluated during ADT. Additional prospective studies are needed to evaluate the long-term effects of bisphosphonates and other the rapies on fracture risk and disease-related outcomes.

Key Words

Bone osteoporosis prostate cancer gonadotropin-releasing hormone agonist antiandrogen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ 2003 Cancer statistics, 2003. CA Cancer J Clin 53:5–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous 1997 Immediate versus deferred treatment for advanced prostatic cancer; initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79:235-246.Google Scholar
  3. 3.
    Bolla M, Gonzalez D, Warde P, et al. 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments]. N Engl J Med 337:295–300.PubMedCrossRefGoogle Scholar
  4. 4.
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer [see comments]. N Engl J Med 341:1781–1788.PubMedCrossRefGoogle Scholar
  5. 5.
    Moul JW 1998 Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt) 12:499–505; discussion 506-508.Google Scholar
  6. 6.
    Garnick MB 1986 Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostage cancer. Results of a prospectively randomized trial. Urology 27:21–28.PubMedGoogle Scholar
  7. 7.
    1999 Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Summary, evidence report/technology assessment: No. 4. Available from: http://ahrq.gov/clinic/prossumm.htmGoogle Scholar
  8. 8.
    Walsh PC, DeWeese TL, Eisenberger MA 2001 A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 166:508–515; discussion 515-516.PubMedCrossRefGoogle Scholar
  9. 9.
    Daniell HW 1997 Osteoporosis after orchiectomy for prostate cancer [see comments]. J Urol 157:439–444.PubMedCrossRefGoogle Scholar
  10. 10.
    Townsend MF, Sanders WH, Northway RO, Graham SD, Jr. 1997 Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545–550.PubMedCrossRefGoogle Scholar
  11. 11.
    Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K 2000 Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449–452.PubMedCrossRefGoogle Scholar
  12. 12.
    Oefelein MG, Ricchuiti V, Conrad W, et al. 2001 Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166:1724–1728.PubMedCrossRefGoogle Scholar
  13. 13.
    Melton LJ, 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H 2003 Fracture risk following bilateral orchiectomy. J Urol 169:1747–1750.PubMedCrossRefGoogle Scholar
  14. 14.
    Schutte HE, Park WM 1983 The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal Radiol 10:1–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Eriksson S, Eriksson A, Stege R, Carlstrom K 1995 Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57:97–99.PubMedCrossRefGoogle Scholar
  16. 16.
    Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C 1999 Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219–1222.PubMedCrossRefGoogle Scholar
  17. 17.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT 2000 Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181–186.PubMedCrossRefGoogle Scholar
  18. 18.
    Smith MR, McGovern FJ, Zietman AL, et al. 2001 Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345:948–955.PubMedCrossRefGoogle Scholar
  19. 19.
    Berruti A, Dogliotti L, Terrone C, et al. 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361–2367; discussion 2367.PubMedCrossRefGoogle Scholar
  20. 20.
    Diamond T, Campbell J, Bryant C, Lynch W 1998 The effect of combined androgen blockade on bone turnover and bone mineral densities in men treatment for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561–1566.PubMedCrossRefGoogle Scholar
  21. 21.
    Eastell R 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736–746.PubMedCrossRefGoogle Scholar
  22. 22.
    Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS 2001 Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 86:511–516.PubMedCrossRefGoogle Scholar
  23. 23.
    Need AG, Horowitz M, Stiliano A, Scopacasa F, Morris HA, Chatterton BE 1996 Vitamin D receptor genotypes are related to bone size and bone density in men. Eur J Clin Invest 26:793–796.PubMedCrossRefGoogle Scholar
  24. 24.
    Eriksen EF, Colvard DS, Berg NJ, et al. 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84–86.PubMedCrossRefGoogle Scholar
  25. 25.
    Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T 1994 Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91:5227–5231.PubMedCrossRefGoogle Scholar
  26. 26.
    Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC 1997 Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755–1759.PubMedGoogle Scholar
  27. 27.
    Khosla S, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274.PubMedCrossRefGoogle Scholar
  28. 28.
    Greendale GA, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 12:1833–1843.PubMedCrossRefGoogle Scholar
  29. 29.
    Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560.PubMedCrossRefGoogle Scholar
  30. 30.
    Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS 2003 Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204–210.PubMedCrossRefGoogle Scholar
  31. 31.
    Scherr D, Pitts WR, Jr., Vaughn ED, Jr. 2002 Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167:535–538.PubMedCrossRefGoogle Scholar
  32. 32.
    Bilezikian JP, 1999 Osteoporosis in men. J Clin Endocrinol Metab 84:3431–3434.PubMedCrossRefGoogle Scholar
  33. 33.
    Dawson-Hughes B, Harris SS, Krall EA, Dallal, GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676PubMedCrossRefGoogle Scholar
  34. 34.
    Giovannucci E, Rimm EB, Wolk A, et al. 1998 Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58:442–447.PubMedGoogle Scholar
  35. 35.
    Chan JM Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A 1998 Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9:559–566.PubMedCrossRefGoogle Scholar
  36. 36.
    Giovannucci E 1998 Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 9:567–582.PubMedCrossRefGoogle Scholar
  37. 37.
    Diamond TH, Winters J, Smith A, et al. 2001 The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92:1444–1450.PubMedCrossRefGoogle Scholar
  38. 38.
    Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012.PubMedCrossRefGoogle Scholar
  39. 39.
    Taxel P, Fall PM, Albertsen PC, et al. 2002 The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 87:4907–4913.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith MR, Fallon MA, Goode MJ 2003 Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 61:127–131.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  1. 1.Massachusetts General HospitalBoston

Personalised recommendations